Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition

Cancer Research

Volumn 71, Issue 8, 2011, Pages 2959-2968

  Jiang, Yuhui ^a   Xie, Xiaoduo ^a   Li, Zhigang ^a   Wang, Zheng ^a   Zhang, Yixuan ^a   Ling, Zhiqiang ^b   Pan, Yi ^a   Wang, Zhenzhen ^a   Chen, Yan ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; LYSOPHOSPHATIDIC ACID; PROTEIN KINASE B; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAF KINASE TRAPPING TO GOLGI PROTEIN; SERINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL STIMULATION; CELL STRAIN HEPG2; CONTROLLED STUDY; EMBRYO; EPIDERMIS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE MUTATION; GENE SILENCING; GENE TARGETING; HETEROZYGOSITY LOSS; HETEROZYGOTE; HYPERPLASIA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954571639     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4077     Document Type: Article

References (40)

1. Feng L, Xie X, Ding Q, Luo X, He J, Fan F, et al. Spatial regulation of Raf kinase signaling by RKTG. Proc Natl Acad Sci U S A 2007;104:14348-53. (Pubitemid 350003264)
2. Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, et al. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. Carcinogenesis 2008;29:1157-63. (Pubitemid 351958694)
3. Luo X, Feng L, Jiang X, Xiao F, Wang Z, Feng GS, et al. Characterization of the topology and functional domains of RKTG. Biochem J 2008;414:399-406.
4. Jiang Y, Xie X, Zhang Y, Luo X, Wang X, Fan F, et al. Regulation of Gprotein signaling by RKTG via sequestration of the G betagamma subunit to the Golgi apparatus. Mol Cell Biol 2010;30:78-90.
5. Xie X, Zhang Y, Jiang Y, Liu W, Ma H, Wang Z, et al. Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse. Carcinogenesis 2008;29:1632-8.
6. Zhang Y, Jiang X, Qin X, Ye D, Yi Z, Liu M, et al. RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene 2010;29:5404-15.
7. Junttila MR, Evan GI. p53-a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-9.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78. (Pubitemid 24289415)
10. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 1993;7:938-43. (Pubitemid 23225552)
11. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356: 215-21.
12. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
13. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 2008;68:683-92. (Pubitemid 351206743)
14. Kalluri R. EMT: When epithelial cells decide to become mesenchymallike cells. J Clin Invest 2009;119:1417-9.
15. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
16. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-37.
17. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005;24:7443-54. (Pubitemid 41637984)
18. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007;26: 7445-56. (Pubitemid 350158710)
19. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle 2008;7:2991-6.
20. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee- Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8. (Pubitemid 36538623)
21. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, et al. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A 2010;107:2598-603.
22. Roger L, Jullien L, Gire V, Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 2010;123:1295-305.
23. Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Stairs DB, et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 2010;70:4174-84.
24. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basallike/ EMT tumor subtypes depending on p53 status. J Clin Invest 2010;120:3296-309.
25. Aasen T, Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat Protoc 2010;5:371-82.
26. Facchin S, Ruzzene M, Peggion C, Sartori G, Carignani G, Marin O, et al. Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB. Cell Mol Life Sci 2007;64:2680-9. (Pubitemid 350035608)
27. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34. (Pubitemid 27467963)
28. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem 2001;276:19672-7.
29. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82. (Pubitemid 34428742)
30. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, et al. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 1994;9:1899-906. (Pubitemid 24194156)
31. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 1998;273:7024-9. (Pubitemid 28160369)
32. Kuhnel F, Gurlevik E, Wirth TC, Struver N, Malek NP, Muller-Schilling M, et al. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther 2010;18:936-46.
33. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51. (Pubitemid 26413787)
34. Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, Tzao C, et al. SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. Cancer Res 2010;70:543-51.
35. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009;137:87-98.
36. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66.
37. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of betacatenin by activated p53. Mol Cell Biol 2001;21:6768-81.
38. Cagatay T, Ozturk M. P53 mutation as a source of aberrant betacatenin accumulation in cancer cells. Oncogene 2002;21:7971-80. (Pubitemid 35430608)
39. Levina E, Oren M, Ben-Ze'ev A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 2004;23:4444-53. (Pubitemid 38850423)
40. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68. (Pubitemid 350309740)